Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine

Biochemical Pharmacology

Volumn 59, Issue 10, 2000, Pages 1253-1263

  Parent, Marise B ^a   Habib, Marie K ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amino acids; Antidepressants; Monoamine oxidase; Monoamines; Panic disorder; Phenelzine

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; ALANINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMINO ACID; ASPARAGINE; BRAIN MONOAMINE; DOPAMINE; GLUTAMINE; GLYCINE; MONOAMINE; NORADRENALIN; PHENELZINE; SERINE; SEROTONIN;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT;

AMINO ACIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; BRAIN; MALE; MONOAMINE OXIDASE; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0034657647     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00244-6     Document Type: Article

References (56)

1. Ashok RB and Sheehan DV, Somatic treatment strategies in panic disorder. In: Panic Disorder: Clinical, Biological, and Treatment Aspects (Eds. Asnis GM and van Praag HM), pp. 279-313. Wiley, New York, 1995.
2. Ballenger J.C. Pharmacotherapy of the panic disorders. J Clin Psychiatry. 47:(Suppl):1986;27-32.
3. Johnson M.R., Lydiard R.B., Ballenger J.C. MAOIs in panic disorder and agoraphobia. Kennedy S.H. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. 1994;205-224 American Psychiatric Press, Washington, DC.
4. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs Correlation with changes in monoamine-oxidase activity and monoamine levels . Neuropharmacology. 37:1998;927-935.
5. Paslawski T., Treit D., Baker G.B., George M., Coutts R.T. The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA. Psychopharmacology (Berl). 127:1996;19-24.
6. Parent M.B., Habib M.K., Baker G.B. Task-dependent effects of the antidepressant/antipanic drug phenelzine on memory. Psychopharmacology (Berl). 142:1999;280-288.
7. Baker G.B., LeGatt D.F., Coutts R.T., Dewhurst W.G. Rat brain concentrations of 5-hydroxytryptamine following acute and chronic administration of MAO-inhibiting antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 8:1984;653-656.
8. Baker GB, Greenshaw AJ and Coutts RT, Chronic administration of monoamine oxidase inhibitors: Implications for interactions between trace amines and catecholamines. In: Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms (Eds. Dahlstrom A, Belmaker RH and Sandler M), pp. 569-572. Alan R. Liss, New York, 1988.
9. Blier P., de Montigny C., Azzaro A.J. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors. Electrophysiological studies in rat central nervous system. J Pharmacol Exp Ther. 237:1986;987-994.
10. 2-Acetylphenelzine Effects on rat brain GABA, alanine, and biogenic amines . Naunyn Schmiedebergs Arch Pharmacol. 343:1991;478-482.
11. McKim R.H., Calverley D.G., Dewhurst W.G., Baker G.B. Regional concentrations of cerebral amines Effects of tranylcypromine and phenelzine . Prog Neuropsychopharmacol Biol Psychiatry. 7:1983;783-786.
12. Perry T.L., Hansen S. Sustained drug-induced elevation of brain GABA in the rat. J Neurochem. 21:1973;1167-1175.
13. Popov N., Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of γ-aminobutyric acid in rat brain. J Neurochem. 16:1969;899-907.
14. Wong J.T.P., Baker G.B., Coutts R.T., Dewhurst W.G. Long-lasting elevation of alanine in brain produced by the antidepressant phenelzine. Brain Res Bull. 25:1990;179-181.
15. Baker G.B., Wong J.T.F., Yeung J.M., Coutts R.T. Effects of the antidepressant phenelzine on brain levels of γ-aminobutyric acid (GABA). J Affect Disord. 21:1991;207-211.
16. McManus D.J., Baker G.B., Martin I.L., Greenshaw A.J., McKenna K.F. Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-T activity in the rat brain. Biochem Pharmacol. 43:1992;2486-2489.
17. Paslawski T.M., Sloley B.D., Baker G.B. Effects of the MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain. Prog Brain Res. 106:1995;181-186.
18. Todd K.G., Baker G.B. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain Effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline . J Affect Disord. 35:1995;125-129.
19. 14C, an irreversible inhibitor of monoamine oxidase - I. Studies in vitro. Biochem Pharmacol. 18:1969;1011-1020.
20. 14C, an irreversible inhibitor of monoamine oxidase - II. Studies in vivo. Biochem Pharmacol. 18:1969;1021-1028.
21. Tipton K.F., Spire I.P.C. Oxidation of 2-phenylethylhydrazine by monoamine oxidase. Biochem Pharmacol. 21:1972;268-270.
22. Yu P.H., Tipton K.F. Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol. 38:1989;4245-4251.
23. Dewar K., Dyck L.E., Durden D.A., Boulton A.A. Involvement of brain trace amines in the behavioural effects of phenelzine. Neurochem Res. 13:1988;113-119.
24. Lyles G.A., Callingham B.A. In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. Biochem Pharmacol. 31:1982;1417-1424.
25. Baker G.B., Coutts R.T., Rao T.S. Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine. Br J Pharmacol. 92:1987;243-255.
26. Sloley B.D., Kah O., Trudeau V.L., Dulka J.G., Peter R.E. Amino acid neurotransmitters and dopamine in brain and pituitary of the goldfish Involvement in the regulation of gonadotropin secretion . J Neurochem. 58:1992;2254-2262.
27. Breslow M.F., Fankhauser M.P., Potter R.L., Meredith K.E., Misiaszek J., Hope D.G. Jr. Role of γ-aminobutyric acid in antipanic drug efficacy. Am J Psychiatry. 146:1989;353-356.
28. Shear M.K. Pathophysiology of panic A review of pharmacologic provocative tests and naturalistic monitoring data . J Clin Psychiatry. 47:(Suppl):1986;18-26.
29. Clarke DD, Lajtha AL and Maker HS, Intermediary metabolism. In, Basic Neurochemistry (Eds. Siegel GJ, Agranoff BW, Albers RW and Molinoff PB), 4th Edn, pp. 541-551. Raven Press, New York, 1989.
30. Norberg K. Changes in the cerebral metabolism induced by hyperventilation at different blood glucose levels. J Neurochem. 26:1976;353-359.
31. Norberg K., Siesjö B.K. Cerebral metabolism in hypoxic hypoxia. II. Citric acid cycle intermediates and associated amino acids. Brain Res. 86:1975;45-54.
32. Chapman A.G., Meldrum B.S., Siesjö B.K. Cerebral metabolic changes during prolonged epileptic seizures in rats. J Neurochem. 28:1977;1025-1035.
33. Folbergrová J., Ljunggren B., Norberg K., Siesjö B.K. Influence of complete ischemia on glycolytic metabolites, citric acid cycle intermediates, and associated amino acids in the rat cerebral cortex. Brain Res. 80:1974;265-279.
34. Erecinska M., Nelson D., Nissim I., Daikhin Y., Yudkoff M. Cerebral alanine transport and alanine aminotransferase reaction Alanine as a source of neuronal glutamate . J Neurochem. 62:1994;1953-1964.
35. Thomson A.M. Glycine modulation of the NMDA receptor-channel complex. Trends Neurosci. 12:1989;349-353.
36. Stryer L, Biochemistry, 2nd Edn, p. 502. W.H. Freeman, San Francisco, 1981.
37. Paulsen R.E., Odden E., Fonnum F. Importance of glutamine for γ-aminobutyric acid synthesis in rat neostriatum in vivo. J Neurochem. 51:1988;1294-1299.
38. Peng L., Hertz L., Huang R., Sonnewald U., Petersen S.B., Westergaard N., Larsson O.M., Schousboe A. Utilization of glutamine and of TCA cycle constituents as precursors of transmitter glutamate and GABA. Dev Neurosci. 15:1993;367-377.
39. McGilvery R.W., Goldstein G.W. Biochemistry A Functional Approach . 3rd Edn. 1983;W.B. Saunders, Philadelphia.
40. Conradi N.G., Nystrom B., Hamberger A., Sourander P. Changes in brain temperature and free amino acids in normal and protein deprived suckling rats exposed to room temperature. Neurochem Res. 13:1988;657-661.
41. Milev P., Meyer-Puttlitz B., Margolis R.K., Margolis R.U. Complex-type asparagine-linked oligosaccharides on phosphacan and protein-tyrosine phosphatase-ζ/β mediate their binding to neural cell adhesion molecules and tenascin. J Biol Chem. 270:1995;24650-24653.
42. Sorkin B.C., Hoffman S., Edelman G.M., Cunningham B.A. Sulfation and phosphorylation of the neural cell adhesion molecule. Science. 225:1984;1476-1478.
43. Masu M., Nakajima Y., Moriyoshi K., Ishii T., Akazawa C., Nakanashi S. Molecular characterization of NMDA and metabotropic glutamate receptors. Ann NY Acad Sci. 707:1993;153-164.
44. Rodwell V.W. Biosynthesis of the nutritionally nonessential amino acids. Murray R.K., Granner D.K., Mayes P.A., Rodwell V.W. Harper's Biochemistry. 1996;293-298 Appleton & Lange, Norwalk, CT.
45. Yudkoff M. Diseases of amino acid metabolism. Siegel G.J., Agranoff B.W., Albers R.W., Fisher S.K., Uhler M.D. Basic Neurochemistry Molecular, Cellular, and Medical Aspects . 6th Edn :1999;887-915 Lippincott-Raven Publishers, Philadelphia.
46. von Essen C., Rydenhag B., Nystrom B., Mozzi R., van Gelder N., Hamberger A. High levels of glycine and serine as a cause of the seizure symptoms of cavernous angiomas? J Neurochem. 67:1996;260-264.
47. Bonilla E., Prasad A.L., Arrieta A. Huntington's disease Studies on brain free amino acids . Life Sci. 42:1988;1153-1158.
48. Chouinard M.L., Gaitan D., Wood P.L. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex Comparison of normal, Parkinson, and Alzheimer tissues . J Neurochem. 61:1993;1561-1564.
49. Hashimoto A., Oka T., Nishikawa T. Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis. Neuroscience. 66:1995;635-643.
50. Kumashiro S., Hashimoto A., Nishikawa T. Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res. 681:1995;117-125.
51. Nagata Y., Horiike K., Maeda T. Distribution of free D-serine in vertebrate brains. Brain Res. 634:1994;291-295.
52. Mitoma J., Furuya S., Hirabayashi Y. A novel metabolic communication between neurons and astrocytes Non-essential amino acid L-serine released from astrocytes is essential for developing hippocampal neurons . Neurosci Res. 30:1998;195-199.
53. Mitoma J., Kasama T., Furuya S., Hirabayashi Y. Occurrence of an unusual phospholipid, phosphatidyl-L-threonine, in cultured hippocampal neurons. Exogenous L-serine is required for the synthesis of neuronal phosphatidyl-L-serine and sphingolipids. J Biol Chem. 273:1998;19363-19366.
54. Gey K.F., Pletscher A. Activity of monoamine oxidase in relation to the 5-hydroxytryptamine and norepinephrine content of the rat brain. J Neurochem. 6:1961;239-243.
55. Hampson D.R., Baker G.B., Coutts R.T. Neurochemical changes in rat brain amines after short- and long-term inhibition of monoamine oxidase by a low dose of tranylcypromine. Biol Psychiatry. 23:1988;227-236.
56. Dyck L.E., Juorio A.V., Durden D.A., Boulton A.A. Effect of chronic deuterated and non-deuterated phenelzine on rat brain monoamines and monoamine oxidase. Naunyn Schmiedebergs Arch Pharmacol. 337:1988;279-283.